Methods and compositions for diagnosing and monitoring transplant rejection

• US 7,691,569 B2
• Filed: 04/24/2003
• Issued: 04/06/2010
• Est. Priority Date: 04/24/2002
• Status: Active Grant

• Current Assignee: CareDx, Inc.
• Original Assignee: XDx Incorporated
• Inventors: Ly, Ngoc, Prentice, James, Morris, MacDonald, Woodward, Robert, Wohlgemuth, Jay, Rosenberg, Steven, Fry, Kirk
• Primary Examiner(s): Martinell; James
• Application Number:
  US10/511,937
• Publication Number:
  US 20060088836A1
• Time in Patent Office: 2,539 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6881 for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6888 for detection or identification of organisms
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/6863 Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Abstract

Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described.

Claims

1. A method of assessing the immune status of an individual comprising detecting the expression level of one or more genes expressed at different levels depending upon the rate of hematopoiesis or the distribution of hematopoietic cells along their maturation pathway in said individual, wherein said one or more genes comprise the nucleotide sequence of SEQ ID NO:

52.

2. The method of claim 1 wherein said expression level is detected by measuring the RNA level expressed by said one or more genes.

3. The method of claim 2, further including isolating RNA from said patient prior to detecting said RNA level expressed by said one or more genes.

4. The method of claim 2 wherein said RNA level is detected by PCR.

5. The method of claim 2 wherein said RNA level is detected by hybridization.

6. The method of claim 2 wherein said RNA level is detected by hybridization to an oligonucleotide.

7. The method of claim 6 wherein said oligonucleotide comprises DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.